











KHK4083
KY1005



Dupilumab — IL-4R α

Th2

Tezepelumab — TSLP

IL-4

IL-5

IL-13

IL-31

Mepolizumab

Omalizumab

Lebrikizumab
Tralokinumab

innate immunity barrier ↓


CD20

Rituximab

B cell

IgE


Eos




IL-4R α

EPITHELIUM

Dupilumab




MC



BAS

Nemolizumab

IL-31R α



NEURON

*Heterogeneous population
of asthma/CSU/AE*



**TOOLBOX
DIAGNOSTICS**

Machine learning/App

Molecular
diagnostics

Clinical diagnostics

Laboratory
diagnostics

**TOOLBOX
THERAPY**

Primary prevention
(stratification/
emollients)

Secondary prevention
Avoidance of trigger
factors

Causative
immunotherapy

Symptomatic
topicals

Symptomatic
conventional systemics/
small molecules

Symptomatic
biologics

**Tailored therapeutic
approach**